Moreover, the combination of ICIs (immune checkpoint inhibitors) with anti-VEGF (vascular endothelial growth factor) drugs for the treatment of renal cancer may increase the risk of cardiovascular events, according to a meta-analysis. This evidence concerns the gene VEGFA and renal carcinoma.